SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I_Banker who wrote (327)1/5/2005 7:00:52 PM
From: idahoranch1  Read Replies (1) of 371
 
Sjogrens is an autoimmune disease that stops glands from secreting fluids, so the patient usually can't make tears or syliva as an example. It can get worse for them as it can effect other organs that are needed for functioning normaly. The important aspect as far as investigating a drug for it is that it is much easier to see real, physical results with Sjogrens than with lupus, you either have spit or you don't. Lupus responses depend on things that are subjective, like pain and fatigue, that are harder to measure.

Yes, the company has CD20 in clinical trials now, and they don't say much about that at all, but it is an important deal for us, especially if CD20 and CD22 together are better than Rituxan alone.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News